Molecular Health Technologies LLC, headquartered in New Jersey, U.S.A. in partnership with Aquanova AG headquartered in Darmstadt, Germany, is proud to announce the publication of a human clinical trial demonstrating that NovaSOL® Curcumin is the now the gold standard in bioavailable curcumin.
The gold standard in bioavailable curcumin has just been established through a two-year independent cross-over human clinical trial conducted by the European Ministry of Education and Research in conjunction with three universities by means of a network research grant (01EA1334A). The peer-reviewed bioavailability results were recently published in Molecular Nutrition and Food Research. The data demonstrates that NovaSOL Curcumin is at the head of the class demonstrating extraordinary bioavailability increases averaging 185x (AUC) and topping 270x (AUC) for women and increasing C-Max levels exponentially.
The study examined the bioavailability of native curcumin, micronized curcumin powder, and NovaSOL Curcumin and the Aquanova NovaSOL mimetic liquid solubilisates demonstrated exponential superiority over all other bioavailable curcumin compounds. Extrapolating the data from the published clinical, consumers will benefit dramatically from consuming relatively low doses of NovaSOL Curcumin (about 80 to 90 mg per day) as that is the bio-equivalent dose of 12 to 15 grams of curcumin powder.
The amazing anti-inflammatory properties of curcumin are well documented, and while consumers are we aware of the benefits, they are keenly aware of the poor absorption properties of the compound. Curcumin powder does not provide the absorption into the body that consumers require for maximum results. More bioavailable forms of curcumin have been introduced, but the liquid micelles of NovaSOL Curcumin are clinically proven to be the most bioavailable form and is available for capsules and softgels.